Europeans enjoy a durable comfort when American healthcare makes headlines: whatever the scandal, it could not happen here. Our systems are public, our incentives gentler, our insurers tamer. The comfort is usually earned. This time it deserves a closer look, because the story unfolding in the United States is not really about American insurance. It is about what happens when health data becomes money, and on that front, Europe is travelling the same road with a polite delay.
The audit wave, briefly
The American programme under scrutiny is Medicare Advantage, in which private insurers deliver public health coverage to more than thirty million older citizens, paid monthly according to how ill each member’s records indicate they are. Diagnoses drive risk scores; risk scores drive payments. The design rewards caring for the sick. It also, inevitably, rewards recording sickness.
After years of warnings, enforcement arrived in force. In March 2026, the US Department of Justice concluded a 117.7 million dollar settlement with a major insurer whose chart-review programmes, prosecutors argued, systematically added diagnosis codes while almost never removing unsupported ones. The same spring, federal auditors published reviews of three insurance plans finding that 81 to 91 percent of sampled high-risk diagnosis codes lacked adequate documentation in the medical record. The characteristic error was almost poignant: conditions patients once had, recorded as though still active.
The machinery of verification has scaled to match. The audit programme, known as RADV, Risk Adjustment Data Validation, has grown from roughly forty reviewers to some two thousand certified coders working quarterly cycles, assisted by AI, with sampled error rates extrapolated across entire contracts and the difference recovered. American health plans now circulate preparation documents with the anxious diligence of students before finals; the standard RADV audit checklist runs from evidence trails for every diagnosis to mock audits and named response teams, and reading one is the fastest way to grasp how seriously the industry now takes verification.
Congressional advisors estimate the excess payments accumulated over the lax years in the tens of billions of dollars annually. That is the price of letting an incentive run fifteen years ahead of its audit.
Why Europe is not exempt
The European instinct is to file this under American excess. The instinct misses how much of Europe’s own health policy now rests on the same foundation: money following recorded data.
Consider the direction of travel. Germany’s risk structure compensation scheme, the Morbi-RSA, redistributes funds among sickness funds based on the documented morbidity of their members, and has already produced its own documentation-inflation controversies and reform rounds. The Netherlands runs sophisticated risk equalisation among competing insurers, with recorded diagnoses among the inputs. England’s NHS allocates to integrated care systems using population-need formulas and is expanding outcome-linked payment. Across the continent, value-based procurement, disease registries, and performance frameworks all convert clinical records into financial flows.
None of these is Medicare Advantage. The incentives are weaker, the public backstops stronger. But the structural truth is identical: wherever documentation determines allocation, documentation acquires a market value, and market values attract optimisation. The American case is distinctive only in scale and in how long verification was deferred.
Europe is also legislating its way deeper into the data-money nexus. The European Health Data Space will standardise and mobilise health records across borders for care, research, and policy. It is a genuinely ambitious project, and it multiplies exactly the surface the Americans are now auditing: machine-readable clinical data with institutional consequences attached.
The transferable lessons
Watched from Brussels, Berlin, or London, the American reckoning offers three lessons at a fraction of the original tuition.
Build verification alongside incentive, not after it. The US audited a fifteen-year-old programme; the gap is where the billions went. European schemes that tie funds to recorded morbidity should assume gaming from day one and fund the audit capacity to match, before headlines force it.
Require provenance. American regulators now discount diagnoses that cannot be traced to a genuine clinical encounter, a rule that instantly devalued warehouses of retrospectively mined codes. Any European framework consuming clinical data for allocation should adopt the same principle early: data with money attached needs a verifiable origin.
Watch for asymmetric correction. The forensic tell in every American enforcement action was one-directional review: quality programmes that only ever found errors increasing payment. Honest data quality is bidirectional. European regulators, and boards of sickness funds and integrated care systems, should learn to ask the simple question that undid the American programmes: how many codes did your reviews remove?
The closing thought
There is a final, more optimistic export. The audit wave is forcing American health data toward a standard worth borrowing: every consequential clinical data point encounter-linked, evidence-backed, explainable, and inspectable years later. Call it defensibility. It is the standard the EU AI Act already gestures at for high-risk systems, arriving in healthcare ahead of schedule because nine-figure settlements are excellent teachers.
Europe has the luxury of adopting the standard before the scandal rather than after it. That is the whole advantage of watching someone else’s audit. The comfortable thought that it could not happen here is available as always. The wiser thought is that it need not, provided we treat the American decade as the free syllabus it is.
